ArticleCancer research2013
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 3 syntheses or guidelines pooled it, 152 citations in OpenAlex.
- Recent Advances in the Therapeutic Potential of Cannabinoids Against Gliomas: A Systematic Review (2022-2025).Pharmacology research & perspectives · 2025Pooled it
- Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas.Journal of neuro-oncology · 2014Pooled it
- Cannabidiol effects in stem cells: A systematic review.BioFactors (Oxford, England)Pooled it
- Medical Cannabis and the Hallmarks of Cancer: A Critical Narrative Review.International journal of molecular sciences · 2026Review
- Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems.Molecular pharmaceutics · 2026Review
- Acute anti-proliferative and anti-migratory effects of cannabidiol on C6 rat glioma, SH-SY5Y human neuroblastoma, and HT22 mouse hippocampal neuronal cell cultures.Frontiers in toxicology · 2026Article
- Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression.Journal of translational medicine · 2025Article
- Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade.The Journal of clinical investigation · 2025Article
- Article
- Toward the Treatment of Glioblastoma Tumors Using Photoactivated Chemotherapy: In Vitro Evaluation of Efficacy and Safety.ACS pharmacology & translational science · 2025Article
- One-carbon-mediated purine synthesis underlies temozolomide resistance in glioblastoma.Cell death & disease · 2024Article
- Elevated Cellular Uptake of Succinimide- and Glucose-Modified Liposomes for Blood-Brain Barrier Transfer and Glioblastoma Therapy.Biomedicines · 2024Article
- Cannabidiol and fluorinated derivative anti-cancer properties against glioblastoma multiforme cell lines, and synergy with imidazotetrazine agents.BJC reports · 2024Article
- From bench to bedside: the application of cannabidiol in glioma.Journal of translational medicine · 2024Review
- Research Progress on the Mechanism of the Antitumor Effects of Cannabidiol.Molecules (Basel, Switzerland) · 2024Review
- A Novel Non-Psychoactive Fatty Acid from a Marine Snail,Molecules (Basel, Switzerland) · 2024Article
- The potential protective and therapeutic effects of cannabidiol oil on experimental Leukemia induced by DMBA in male rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines.Scientific reports · 2024Article
- Article
- Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review.Pharmacological reports : PR · 2023Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma is the most common form of primary adult brain tumors. A majority of glioblastomas grow invasively into distant brain tissue, leading to tumor recurrence, which is ultimately incurable. It is, therefore, essential to discover master regulators that control glioblastoma invasiveness and target them therapeutically. We show here that the transcriptional regulator Id-1 plays a critical role in modulating the invasiveness of glioblastoma cell lines and primary glioblastoma cells. Id-1 expression levels positively correlate with glioma cell invasiveness in culture and with histopathologic grades in patient biopsies. Id-1 knockdown dramatically reduces glioblastoma cell invasion that is accompanied by profound morphologic changes and robust reduction in expression levels of "mesenchymal" markers, as well as inhibition of self-renewal potential and downregulation of glioma stem cell markers. Importantly, genetic knockdown of Id-1 leads to a significant increase in survival in an orthotopic model of human glioblastoma. Furthermore, we show that a nontoxic compound, cannabidiol, significantly downregulates Id-1 gene expression and associated glioma cell invasiveness and self-renewal. In addition, cannabidiol significantly inhibits the invasion of glioblastoma cells through an organotypic brain slice and glioma progression in vivo. Our results suggest that Id-1 regulates multiple tumor-promoting pathways in glioblastoma and that drugs targeting Id-1 represent a novel and promising strategy for improving the therapy and outcome of patients with glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.